News &amp; Updates

Enzalutamide is a more effective therapy than abiraterone for patients with metastatic castration-resistant prostate cancer, but it appears to significantly increase the risk of side effects, particularly fatigue, suggests a study.

Enzalutamide bests abiraterone in treatment of castration-resistant prostate cancer

Pharmacist-driven MTX protocol reduces length of stay, kidney injury

Implementing a pharmacist-driven protocol for high-dose methotrexate (MTX) management leads to a significant decrease in inpatient length of stay and kidney injury, according to a study.

Pharmacist-driven MTX protocol reduces length of stay, kidney injury

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

Treatment with pazopanib is both effective and well tolerated in good performance status patients with relapsed, advanced nonadipocytic soft tissue sarcomas, results of a multicentre retrospective study have shown.

Pazopanib tolerable, improves survival in metastatic soft tissue sarcoma

Cyclophosphamide-free chemo may promote menses resumption

Breast cancer patients receiving treatment with a cyclophosphamide-free chemotherapy regimen are likely to resume their menses, according to a phase III trial.

Cyclophosphamide-free chemo may promote menses resumption

Fitness trackers motivate cancer survivors to exercise more

26 May 2021 by

Cancer survivors who use wearable activity trackers (WATs) tend to meet physical activity (PA) recommendations more often, according to a recent study.

Fitness trackers motivate cancer survivors to exercise more

26 May 2021

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

Children treated with BRAF and MEK inhibitors are prone to cutaneous reactions, many of which result in alterations or interruptions in oncologic therapy, reports a study.

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

Vitamin K may shield against pancreatic cancer

Dietary intakes of phylloquinone and dihydrophylloquinone appear to yield a beneficial effect on the risk of developing pancreatic cancer, a study reports.

Vitamin K may shield against pancreatic cancer

$Decitabine plus camrelizumab shows activity against relapsed, refractory cHL$

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

Treatment with the combination of decitabine plus camrelizumab yields high response rates and long-term benefits in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed programmed death-1 (PD-1) inhibitors, as shown in a study.

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL